Navigating Complexity: The Growth of the Pharmaceutical Third-Party Logistics Market Through 2030

1. Summary

• The pharmaceutical third-party logistics (3PL) market is on the cusp of a significant transformation, with projections indicating a remarkable ascent to USD 228.54 billion by the year 2030, representing a compound annual growth rate (CAGR) of 8.95%. This anticipated growth trajectory is driven by several factors, notably the escalating complexities of global supply chains which pharmaceutical companies must adeptly navigate. The industry is experiencing a paradigm shift, where logistics functions are increasingly outsourced to third-party specialists, allowing pharmaceutical entities to refocus on their core competencies, such as research and development and product innovation. This emphasis on collaboration with 3PL providers paves the way for heightened operational efficiencies and enhanced service delivery timelines.

• One of the most critical drivers of this burgeoning market is the surging demand for temperature-sensitive pharmaceuticals, particularly biologics and vaccines. The need for stringent temperature control throughout the storage and transportation phases cannot be overstated; any lapse in this area could compromise the efficacy of these sensitive products. As the prevalence of chronic diseases rises and the landscape of medicine becomes increasingly tailored, 3PL providers are finding themselves at the forefront of meeting these specialized logistics needs. Their expertise in maintaining the integrity of these products through rigorous cold chain logistics is indispensable in the current market milieu.

• Furthermore, the regulatory environment is evolving at a fast pace, imposing stricter guidelines that necessitate compliance and transparency throughout the supply chain. This growing regulatory scrutiny enhances the reliance on expert logistics providers who are well-versed in navigating these complexities. As the industry continues to advance, the emphasis on technology integration—such as artificial intelligence and the Internet of Things—will become paramount in enhancing supply chain visibility and operational efficacy.

2. Introduction to the Pharmaceutical Third-Party Logistics Market

• 2-1. Definition and Role of Third-Party Logistics (3PL)

• Third-party logistics (3PL) refers to the outsourcing of logistics and supply chain management functions to an external service provider. In the pharmaceutical sector, 3PL providers manage crucial operations such as transportation, warehousing, and distribution of pharmaceuticals, including temperature-sensitive products. The role of 3PL in the pharmaceutical industry is particularly significant due to the complexities involved in compliance with regulations, the need for specialized handling of delicate drugs, and the necessity for maintaining product efficacy through proper storage and transportation conditions.

• By engaging 3PL services, pharmaceutical companies can focus on their core competencies, such as drug development and marketing, while leveraging the logistics expertise of 3PL providers. This collaboration allows for streamlined operations, cost reduction, and improved service levels. Furthermore, adherence to stringent regulations, such as Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), is critical, as these ensure that pharmaceutical products are securely handled and transported, safeguarding their quality and safety during the supply chain process.

• 2-2. Current Market Landscape

• As of 2024, the global pharmaceutical third-party logistics market is valued at approximately USD 137.25 billion and is projected to grow at a compound annual growth rate (CAGR) of 8.95% through 2030. The expansion of this market is fuelled by various factors, including the increasing complexity of global pharmaceutical supply chains and the rising demand for temperature-sensitive products such as biologics and vaccines. Companies are outsourcing logistics functions to achieve operational efficiencies and comply with regulatory demands, particularly as the pharmaceutical industry navigates an increasingly globalized landscape.

• The market is characterized by a substantial share of branded drugs, which accounted for 39.06% of the 3PL industry in 2024, primarily due to their high margin and established demand. As manufacturers face conveyor issues related to distribution and compliance with evolving regulations, there is a growing reliance on specialized logistics companies capable of addressing these challenges. The surge in demand for cold chain logistics solutions further indicates market trends leaning towards quality assurance for temperature-sensitive pharmaceuticals. As technology evolves, integrating AI and IoT into logistics operations is becoming a norm, subsequently enhancing supply chain visibility and operational effectiveness.

• 2-3. Importance in the Pharmaceutical Industry

• The importance of third-party logistics in the pharmaceutical industry cannot be overstated. As the pharmaceutical landscape grows in complexity, so does the need for reliable logistics systems to ensure that medicines reach their intended markets safely and effectively. The reliance on 3PL providers is particularly vital for temperature-sensitive products, which require stringent controls to maintain efficacy. This includes not just transportation but also storage in temperature-controlled environments, which is crucial for pharmaceuticals like biologics and vaccines, where any deviation from recommended conditions can compromise product integrity.

• Moreover, the increasing regulatory scrutiny in the pharmaceutical sector underscores the necessity for logistics solutions that comply with global standards. 3PL providers are essential for adhering to regulations such as the Drug Supply Chain Security Act (DSCSA) in the USA, which aims to enhance the security of the pharmaceutical supply chain. By ensuring compliance with these regulations, 3PL services help mitigate risks associated with counterfeiting and ensure that products are traceable from manufacturing to the end consumer. Ultimately, the collaboration between pharmaceutical companies and 3PL not only promotes operational efficiencies but also enhances patient safety and trust in pharmaceutical products.

3. Statistical Overview of Market Data

• 3-1. Market Size and Value Projections

• The global pharmaceutical third-party logistics (3PL) market is witnessing considerable growth, with a projected market size reaching USD 228.54 billion by the year 2030. The market, which was estimated at USD 137.25 billion in 2024, is expected to expand at a robust Compound Annual Growth Rate (CAGR) of 8.95% from 2025 to 2030. This growth trajectory is attributable mainly to factors such as the increasing complexity of global supply chains, evolving regulatory demands, and a rising inclination towards outsourcing logistics functions by pharmaceutical companies. As firms navigate an increasingly intricate regulatory landscape focused on stringent compliance protocols for temperature-sensitive products, the demand for expertise offered by 3PL providers grows manifold. Moreover, the emergence of novel therapies, including biologics and gene therapies, compounds the logistical challenges that pharmaceutical companies face, necessitating specialized logistics solutions.

• In terms of market contributions by product type, the branded drugs segment has captured the majority share, standing at 39.06% as of 2024. This segment's dominance is underpinned by the higher value and established consumer demand for these products. Furthermore, the cell therapy market is projected to experience the highest growth rate during the forecast period, estimated at 9.86%. This surge is largely driven by the increasing adoption of cell-based therapies, which are inherently complex and require highly specialized logistics services to ensure their viability throughout the supply chain.

• 3-2. Growth Rate Analysis

• The analysis of growth rates within the pharmaceutical third-party logistics sector reveals a remarkable resilience in the face of ongoing market complexities. An anticipated CAGR of 8.95% reflects the dynamic nature of this industry, influenced significantly by external factors such as regulatory requirements and the expanding scope of drug formulations. Moreover, the rapid advancement in cold chain logistics is a critical component of this growth, driven primarily by the burgeoning demand for temperature-sensitive pharmaceuticals including biologics and vaccines. As the pharmaceutical landscape shifts towards more personalized and targeted therapies, the need for innovative logistics solutions to ensure product integrity and compliance with stringent storage conditions has become more pronounced.

• Key market drivers contributing to this robust growth rate include the rising trend of e-commerce in pharmaceuticals and increased demand for outsourcing logistics capabilities. Pharmaceutical companies are increasingly focusing on their core competencies, prompting many to partner with third-party logistics providers. This trend not only aids in reducing operational costs but also enhances efficiency in logistics operations. Additionally, the market is poised to grow as technological advancements such as artificial intelligence and blockchain foster enhanced supply chain visibility and efficiency, further solidifying the case for outsourcing logistics functions.

• 3-3. Regional Market Insights

• Regionally, North America accounts for the largest market share in the pharmaceutical third-party logistics sector, holding an impressive 38.3% share as of 2024. This dominance is due in part to North America’s well-established healthcare infrastructure and advanced logistics networks, coupled with substantial demand for pharmaceutical products. A high concentration of pharmaceutical manufacturers and distributors within the United States, particularly in the biopharmaceutical sector, necessitates robust logistical support, leading to increased reliance on 3PL providers.

• In Europe, growth in the pharmaceutical 3PL market is driven by a booming pharmaceutical industry and the increasing emphasis on regulatory compliance and temperature-controlled logistics. The region's expansive pharmaceutical manufacturing capabilities necessitate specialized logistics solutions tailored for biologics and other temperature-sensitive drugs. As regulatory frameworks evolve and demands for novel therapies escalate across various healthcare systems, third-party logistics providers are expected to play a pivotal role in facilitating efficient healthcare delivery in these markets.

4. Analyzing Growth Factors and Market Trends

• 4-1. Drivers of Market Growth

• The pharmaceutical third-party logistics (3PL) market is currently experiencing significant growth, primarily driven by several key factors. At the forefront is the increasing complexity of global supply chains that pharmaceutical companies must navigate. As noted in various industry reports, the intricate nature of these supply chains often requires outsourcing logistics functions to specialized providers, allowing pharmaceutical companies to focus on their core competencies such as research and development while leveraging expert logistics capabilities. This shift enhances operational efficiency, reduces costs, and improves service delivery timelines. Additionally, the globalization of the pharmaceutical industry fosters a competitive environment that necessitates robust logistical solutions catering to diverse regulatory standards across regions.

• Another critical driver is the rising demand for temperature-sensitive products, such as biologics and pharmaceuticals requiring rigorous temperature controls during storage and transportation. The increasing prevalence of chronic diseases and the consequent demand for innovative therapeutics, particularly those based on biologics, significantly impact the logistics landscape. These products often necessitate specialized cold chain solutions that ensure their integrity. As a result, investments in advanced cold chain logistics solutions have surged, prompting 3PL providers to enhance their capabilities to meet this growing need effectively.

• Furthermore, strict regulations and compliance requirements regarding the handling and transportation of pharmaceuticals accentuate the reliance on 3PL providers with the requisite certifications and expertise. They are increasingly tasked with ensuring compliance with Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), creating a fertile ground for the growth of the 3PL market.

• 4-2. Impact of Global Supply Chain Complexity

• The complexity of global supply chains profoundly impacts the pharmaceutical third-party logistics market, presenting both challenges and opportunities. As noted, the globalization of trade and an increase in the variety of pharmaceutical products necessitate sophisticated logistics strategies. Companies are compelled to adopt integrated logistics solutions that can handle not only domestic but also international shipping demands, reflecting the need for greater flexibility and responsiveness in delivery capabilities.

• Moreover, the evolving regulatory environment further complicates these supply chains. Pharmaceutical companies must navigate varying compliance requirements across different markets, which can be cumbersome and resource-intensive if managed internally. This complexity encourages firms to seek partnerships with 3PL providers skilled in regulatory compliance, allowing them to maintain a focus on innovation and market expansion. As reported, the complexities arising from varied regulatory landscapes include serialization and traceability mandates under the Drug Supply Chain Security Act (DSCSA) in the U.S., which require detailed tracking of pharmaceuticals throughout the supply chain.

• Additionally, disruptions caused by geopolitical tensions, trade wars, and global health crises, such as the COVID-19 pandemic, have underscored the need for resilient supply chains. Companies with flexible, diversified supply chain strategies that incorporate 3PL solutions are better equipped to manage risks effectively, ensuring uninterrupted delivery of essential medications and therapeutics. Such strategic shifts towards more agile logistics frameworks are expected to drive growth in the pharmaceutical 3PL market as companies strive to enhance their supply chain resilience.

• 4-3. Emerging Trends in Cold Chain Logistics

• Emerging trends in cold chain logistics are reshaping the pharmaceutical 3PL landscape, driven largely by innovations in technology and a growing emphasis on compliance. With the continuing expansion of biologics and personalized medicine, there is an escalating demand for specialized cold chain logistics that can maintain the efficacy of sensitive pharmaceutical products throughout the supply chain. This trend highlights the critical role that temperature control plays in preserving the potency of biologics and biosimilars, many of which require strict temperature management during transportation.

• Technological advancements are pivotal in this evolution. The integration of Internet of Things (IoT) devices for real-time temperature monitoring, artificial intelligence (AI) for predictive analytics, and blockchain for secure transaction tracking enhances operational efficiencies and ensures compliance with regulatory mandates. For instance, companies are leveraging AI-driven systems not just for monitoring but also for route optimization and risk mitigation, which significantly improves the overall effectiveness of cold chain logistics. Real-time temperature monitoring systems reduce risks associated with temperature excursions, addressing potential spoilage and compliance failures.

• Furthermore, the landscape is witnessing an increased focus on sustainability practices within cold chain logistics. Companies are exploring eco-friendly materials and energy-efficient refrigeration technologies, which not only appeal to environmentally conscious stakeholders but also align with long-term operational cost reduction goals. This commitment to sustainability, coupled with enhanced cold chain infrastructures, enables 3PL providers to cater to a broader range of temperature-sensitive products, thereby solidifying their position in the rapidly evolving pharmaceutical logistics market.

5. Profiles of Key Players in the Market

• 5-1. CEVA Logistics

• CEVA Logistics has established itself as a significant player in the pharmaceutical third-party logistics (3PL) sector through strategic expansions and investment in specialized capabilities. The company is known for its comprehensive logistics solutions, tailored specifically to the needs of the healthcare and pharmaceutical industries. With a commitment to maintaining the integrity of temperature-sensitive products, CEVA employs rigorous cold chain management practices, ensuring compliance with stringent regulatory requirements. This focus on quality has enabled CEVA to build strong partnerships with pharmaceutical manufacturers and healthcare providers, enhancing their operational efficiencies and facilitating the distribution of critical medications. Furthermore, CEVA's investments in technology, such as artificial intelligence and automation, have positioned it to respond effectively to the evolving demands of the pharmaceutical market, providing enhanced tracking and monitoring capabilities for shipments.

• Key to CEVA’s strategy is its extensive global presence, which allows the company to leverage regional expertise and provide customized logistics solutions across various markets. The company's proactive approach to addressing challenges in drug distribution, particularly concerning the transportation of biologics and vaccines, illustrates its commitment to ensuring the safe and timely delivery of pharmaceuticals globally.

• 5-2. Cencora

• Cencora, formerly known as AmerisourceBergen, is a key competitor in the pharmaceutical 3PL market, recognized for its comprehensive distribution network that supports a wide array of pharmaceutical products. The company has built a robust infrastructure that facilitates the swift and reliable delivery of medications, with a particular emphasis on temperature-controlled logistics services that cater to the increasingly specialized needs of the pharmaceutical industry. Cencora's focus on integrating technology into its operations reflects its commitment to innovation, enhancing not only supply chain visibility but also operational efficiency.

• Additionally, Cencora has taken strategic steps to expand its cold chain capabilities in response to the growing market demand for biologics and specialty pharmaceuticals. Their expertise in navigating the complexities of regulatory compliance positions the company favorably within the market, enabling pharmaceutical manufacturers to focus on their core competencies while outsourcing logistics functions to Cencora.

• 5-3. Kuehne+Nagel

• Kuehne+Nagel is a global logistics leader with significant expertise in healthcare and pharmaceutical logistics. The company's extensive network and logistics solutions are meticulously designed to meet the stringent demands of the pharmaceutical sector, providing vital services such as temperature-sensitive transportation and specialized cold chain management. Kuehne+Nagel’s investment in technological advancements, particularly in real-time monitoring and predictive analytics, enhances their logistics operations, allowing them to maintain the quality and integrity of pharmaceutical products throughout the supply chain.

• Furthermore, Kuehne+Nagel's strategic collaborations with pharmaceutical manufacturers places them at the forefront of addressing the evolving challenges in drug distribution, including compliance with various international guidelines. Their proactive measures not only enhance their operational efficiencies but also reinforce customer trust in their logistics capabilities.

• 5-4. Kerry Logistics Network

• Kerry Logistics Network stands out in the pharmaceutical logistics market due to its strategic focus on Asia and extensive network capabilities. The company offers a comprehensive range of services that cater to the unique needs of pharmaceutical clients, including temperature-controlled transport and warehousing solutions. Their commitment to developing and maintaining robust cold chain logistics is a response to the growing requirement for secure and reliable handling of temperature-sensitive pharmaceuticals.

• Moreover, Kerry Logistics has invested significantly in developing their digital capabilities, integrating advanced technologies that provide enhanced visibility and efficiency in logistics processes. By aligning their services with the complex needs of the pharmaceutical sector, they continue to strengthen their market position, allowing clients to navigate supply chain challenges effectively.

• 5-5. Cardinal Health

• Cardinal Health is a prominent player within the pharmaceutical logistics market, leveraging its extensive distribution network to provide innovative solutions tailored to the complexities of healthcare logistics. The company emphasizes reliable storage and transportation services, particularly for temperature-sensitive products, ensuring compliance with regulatory standards at all times. Cardinal Health’s deep sector knowledge enables it to efficiently manage the intricate demands of pharmaceutical distribution, including services related to drug serialization and compliance with the Drug Supply Chain Security Act (DSCSA).

• Through continuous investment in advanced logistics technologies and infrastructure, Cardinal Health actively enhances its operational capabilities, allowing for improved inventory management and real-time tracking of pharmaceuticals. Their broad service offerings position them as a trusted partner for pharmaceutical companies looking to optimize their supply chains in an increasingly complex environment.

• 5-6. McKesson

• McKesson Corporation is a global leader in healthcare logistics and offers extensive services specifically designed for the pharmaceutical sector. Their operations are characterized by a strong focus on enhancing the efficiency of supply chains, particularly for temperature-controlled pharmaceuticals. McKesson's commitment to technology-driven solutions enables it to provide enhanced service offerings, including comprehensive tracking and tracing for pharmaceutical shipments, a vital aspect given the importance of compliance with regulatory standards.

• Additionally, McKesson's expertise in managing large-scale distribution allows pharmaceutical manufacturers to efficiently reach healthcare providers and patients. The company’s continued investments in logistics capabilities underscore its determination to adapt to the evolving landscape of drug distribution, focusing on innovation to meet the increasing demands of the pharmaceutical marketplace.

• 5-7. Eversana

• Eversana is a unique entity in the pharmaceutical logistics space, providing a range of services that extend beyond traditional logistics to comprehensive solutions encompassing commercialization strategies. By integrating logistics with market access capabilities, Eversana offers pharmaceutical companies a holistic approach to navigating supply chain complexities. Their emphasis on temperature-controlled solutions ensures the secure handling of biologics and specialty medications that require meticulous management throughout the distribution process.

• Eversana's investment in leveraging data analytics enhances visibility across supply chains, allowing them to address potential disruptions proactively. This capability aligns with the broader industry trend towards innovative, technology-enabled logistics solutions that enable faster and more efficient distribution of pharmaceuticals.

• 5-8. Knipper Health

• Knipper Health stands out for its focus on providing specialized healthcare logistics solutions that cater specifically to the pharmaceutical sector. Known for its expertise in managing complex distribution needs, particularly for temperature-sensitive products, Knipper Health integrates logistics with critical services such as sample management and compliance solutions. This focus allows them to maintain high standards of quality and compliance throughout their operations.

• Moreover, Knipper Health’s investment in advanced logistics technology enhances the efficiency and reliability of its service offerings, supporting pharmaceutical companies' needs for precise inventory management and timely distribution. Their unique positioning within the market enables them to serve clients effectively by providing tailored logistics solutions that navigate the complexities of pharmaceutical distribution.

6. Conclusion: Future Outlook of the Market

• 6-1. Summary of Key Findings

• The pharmaceutical third-party logistics (3PL) market is on a robust growth trajectory, projected to reach USD 228.54 billion by 2030, at a compound annual growth rate (CAGR) of 8.95%. This growth is largely fueled by increasing complexities in global supply chains, stringent regulatory requirements, and a notable rise in demand for temperature-sensitive products such as biologics and vaccines. Key players are expected to invest heavily in expanding their cold chain logistics capabilities and adopting advanced technologies like IoT and AI, which streamline operations and enhance shipment tracking.

• The market exhibits varying dynamics across different therapeutic areas. Notably, the oncology segment emerged as a leader in market share due to the rising prevalence of cancer and demand for specialized treatment logistics. Concurrently, the growing push towards personalized medicine and cell therapies necessitates highly specialized logistics solutions that can efficiently manage temperature-sensitive deliveries. These trends highlight the critical need for logistics providers to innovate continuously in order to meet these evolving demands.

• 6-2. Implications for Stakeholders

• For stakeholders in the pharmaceutical and logistics sectors, understanding these market dynamics is essential for informed decision-making. Pharmaceutical companies are increasingly leaning on third-party logistics providers to leverage their specialized expertise, particularly in managing cold chain requirements. This shift suggests a growing opportunity for partnerships between pharmaceutical firms and 3PL providers, aiming to optimize costs and efficiency while ensuring regulatory compliance.

• Moreover, as the regulatory landscape becomes more intricate, the need for 3PL providers equipped with the necessary certifications and operational capabilities will become even more pronounced. Companies that can navigate these complexities while providing reliable and compliant logistics solutions will be well-positioned to capture a larger market share.

• 6-3. Recommendations for Navigating Market Dynamics

• To successfully navigate the forthcoming challenges and opportunities within the pharmaceutical third-party logistics market, stakeholders should prioritize investments in cold chain capabilities while integrating advanced technologies. Developing partnerships with tech firms can bolster supply chain visibility and enhance monitoring through real-time tracking systems. Additionally, embracing blockchain technology may facilitate greater transparency and security throughout the supply chain.

• It is equally important for stakeholders to remain agile, adapting logistics strategies to fluctuating regulatory frameworks and industry standards. Engaging in continuous learning and professional development within their teams will equip them with the latest knowledge and skills necessary to respond effectively to market changes. Lastly, exploring emerging markets where demand for pharmaceutical logistics is growth-driven can provide substantial opportunities for expansion and innovation.

Conclusion

• The pharmaceutical third-party logistics market is poised for robust growth, expected to reach USD 228.54 billion by 2030, driven largely by increasing global supply chain complexities, stringent regulatory requirements, and the rising demand for temperature-sensitive products. Key findings underscore the importance of cold chain logistics and the growing prevalence of specialized treatment logistics, particularly in oncology and personalized medicine segments. This landscape necessitates continuous innovation and adaptation in logistics strategies to cater to the evolving needs of the pharmaceutical sector.

• For stakeholders in both the pharmaceutical and logistics domains, grasping these market dynamics is essential for strategic decision-making. As pharmaceutical companies increasingly depend on third-party logistics to navigate the intricate world of cold chain requirements, opportunities for strategic partnerships are likely to proliferate. Moreover, the complexity of the regulatory environment amplifies the need for 3PL providers to possess the necessary certifications and operational expertise, positioning them as vital partners in achieving compliance and efficiency.

• In light of forthcoming challenges and opportunities, stakeholders are encouraged to invest in their cold chain capabilities and integrate advanced technologies into their operations. Partnerships with technological innovators could enhance real-time supply chain visibility and monitoring capabilities. Additionally, a commitment to adaptability and continuous education within teams is vital in equipping organizations with the tools necessary to thrive amid market fluctuations. Exploring burgeoning markets where demand for pharmaceutical logistics is on the rise can also yield significant opportunities for expansion and innovation.

Glossary

• Pharmaceutical Third-Party Logistics (3PL) [Concept]: The outsourcing of logistics and supply chain management functions to an external service provider, specifically for the transportation, warehousing, and distribution of pharmaceuticals.

• Cold Chain Logistics [Concept]: A specialized logistics system for transporting and storing temperature-sensitive products, ensuring that specific temperature ranges are maintained throughout the supply chain.

• CAGR (Compound Annual Growth Rate) [Concept]: A measure used to represent the mean annual growth rate of an investment over a specified period of time longer than one year.

• Good Distribution Practices (GDP) [Document]: A set of guidelines that ensure the proper distribution and storage of pharmaceutical products to maintain their quality and integrity.

• Good Manufacturing Practices (GMP) [Document]: Regulations that require manufacturers to ensure their products are consistently produced and controlled to quality standards.

• Drug Supply Chain Security Act (DSCSA) [Document]: A U.S. law aimed at securing the pharmaceutical supply chain by establishing standards for product tracing and verification.

• Temperature-Sensitive Pharmaceuticals [Concept]: Pharmaceutical products that must be stored and transported within specific temperature ranges to maintain their efficacy and safety.

• Biologics [Product]: Medicines derived from living organisms, often requiring specific handling and storage conditions due to their sensitivity to temperature and environmental factors.

• Supply Chain Visibility [Concept]: The ability to track and monitor inventory levels, orders, and deliveries in real-time throughout the logistics and distribution process.

• Artificial Intelligence (AI) [Technology]: A technology enabling machines to perform tasks that typically require human intelligence, such as predictive analytics in logistics.

• Internet of Things (IoT) [Technology]: A network of physical devices connected to the internet, allowing for real-time data exchange and monitoring, often used for temperature tracking in logistics.

• Temperature-Controlled Environments [Concept]: Specific storage conditions that maintain required temperatures for pharmaceuticals, crucial for ensuring product integrity.

• Personalized Medicine [Concept]: Medical care tailored to the individual characteristics, needs, and preferences of a patient, often reliant on advanced logistics for delivery.

• Cell Therapies [Product]: Treatments that involve the use of living cells to restore or replace damaged tissues or cells, often requiring specialized logistics.

• E-commerce in Pharmaceuticals [Concept]: The online buying and selling of pharmaceutical products, increasing the demand for robust logistics solutions.

Source Documents

• Pharmaceutical Third-Party Logistics Market Report, 2030https://www.grandviewresearch.com/industry-analysis/pharmaceutical-third-party-logistics-market-report
• Pharmaceutical Third-Party Logistics Market Report 2025-2030, with Profiles of CEVA Logistics, Cencora, Kuehne+Nagel, Kerry Logistics Network, Cardinal Health, McKesson, Eversana & Knipper Healthhttps://www.globenewswire.com/news-release/2025/03/10/3039932/0/en/Pharmaceutical-Third-Party-Logistics-Market-Report-2025-2030-with-Profiles-of-CEVA-Logistics-Cencora-Kuehne-Nagel-Kerry-Logistics-Network-Cardinal-Health-McKesson-Eversana-Knipper-.html
• Healthcare Cold Chain Third Party Logistics Market Report, 2030https://www.grandviewresearch.com/industry-analysis/healthcare-cold-chain-third-party-logistics-market-report